Nurotron receives approval for sale in India

Nurotron Biotechnology, headquartered in China, which designs, develops and markets neural-electronic medical devices and systems, received approval from CDSCO to sell its Venus Cochlear Implant System in India


(Photo Courtesy:

The system is a safe, reliable and effective solution for children and adults suffering from severe and profound hearing loss.

Headquartered in New Delhi, CDSCO is India's main regulatory body for pharmaceuticals and medical devices.

CDSCO organization safeguards and enhances the public health by assuring the safety, efficacy and quality of drugs, cosmetics and medical devices.

"This approval by India's primary drug and medical device oversight organization is a major achievement for Nurotron's cochlear implant system," says Mr Chu Li, CEO, Nurotron. "The validation of the efficacy of Nurortron's offerings in the important Indian market confirms the company's position as a global leader in cochlear implant technology."

Nurotron already holds the CE mark in Europe for the Venus Cochlear Implant System, and has received approval to sell in China and Turkey as well.

Leave a Reply Sign in

Notify me of follow-up comments via e-mail address

Post Comment

Survey Box

Union Budget

Has Union budget 2017 addressed all requirements of healthcare industry?

Send this article by email